World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
50
Citations
15146
World Ranking
17434
National Ranking
498

Guillaume Lessene publication distribution in Biology and Biochemistry in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Biology and Biochemistry in 2026. The highlighted bar marks where Guillaume Lessene sits on this spectrum.

47–56 publications: 8 scientists 57–66 publications: 35 scientists 67–76 publications: 106 scientists 77–86 publications: 231 scientists 87–96 publications: 413 scientists 97–106 publications: 546 scientists 107–116 publications: 704 scientists 117–126 publications: 848 scientists 127–136 publications: 980 scientists 137–146 publications: 942 scientists 147–156 publications: 969 scientists 157–166 publications: 949 scientists 167–176 publications: 951 scientists 177–186 publications: 915 scientists 187–196 publications: 787 scientists 197–206 publications: 840 scientists 207–216 publications: 733 scientists 217–226 publications: 708 scientists 227–236 publications: 651 scientists 237–246 publications: 605 scientists 247–256 publications: 510 scientists 257–266 publications: 524 scientists 267–276 publications: 434 scientists 277–286 publications: 417 scientists 287–296 publications: 350 scientists 297–306 publications: 363 scientists 307–316 publications: 315 scientists 317–326 publications: 296 scientists 327–336 publications: 261 scientists 337–346 publications: 240 scientists 347–356 publications: 219 scientists 357–366 publications: 196 scientists 367–376 publications: 154 scientists 377–386 publications: 161 scientists 387–396 publications: 155 scientists 397–406 publications: 145 scientists 407–416 publications: 124 scientists 417–426 publications: 112 scientists 427–436 publications: 132 scientists 437–446 publications: 116 scientists 447–456 publications: 99 scientists 457–466 publications: 81 scientists 467–476 publications: 91 scientists 477–486 publications: 80 scientists 487–496 publications: 80 scientists 497–506 publications: 59 scientists 507–516 publications: 36 scientists 517–526 publications: 46 scientists 527–536 publications: 54 scientists 537–546 publications: 44 scientists 547–556 publications: 43 scientists 557–566 publications: 43 scientists 567–576 publications: 42 scientists 577–586 publications: 25 scientists 587–596 publications: 34 scientists 597–606 publications: 23 scientists 607–616 publications: 33 scientists 617–626 publications: 31 scientists 627–636 publications: 27 scientists 637–646 publications: 25 scientists 647–656 publications: 28 scientists 657–666 publications: 34 scientists 667–676 publications: 18 scientists 677–686 publications: 16 scientists 687–696 publications: 10 scientists 697–706 publications: 12 scientists 707–716 publications: 21 scientists 717–726 publications: 12 scientists 727–736 publications: 12 scientists 737–746 publications: 10 scientists 747–756 publications: 7 scientists 757–766 publications: 13 scientists 767–776 publications: 15 scientists 777–786 publications: 13 scientists 787–796 publications: 9 scientists 797–806 publications: 9 scientists 807–816 publications: 7 scientists 817–826 publications: 4 scientists 827–836 publications: 9 scientists 837–846 publications: 7 scientists 847–856 publications: 3 scientists 857–866 publications: 5 scientists 867–876 publications: 5 scientists 877–886 publications: 11 scientists 887–896 publications: 3 scientists 897–906 publications: 4 scientists 907–916 publications: 7 scientists 917–926 publications: 5 scientists 927–936 publications: 6 scientists 937–946 publications: 6 scientists 947–956 publications: 3 scientists 957–966 publications: 7 scientists 967–976 publications: 2 scientists 977–986 publications: 2 scientists 987–996 publications: 1 scientists 997–1,006 publications: 5 scientists 1,007–1,016 publications: 2 scientists 1,017–1,026 publications: 2 scientists 1,027 publications: 1 scientists 1,028+ publications: 100 scientists
47 publications 1,028+

This scientist: 134 publications — 19th percentile

19% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,028 publications or more.

Guillaume Lessene D-index placement in Biology and Biochemistry in 2026

The chart shows the D-index (discipline H-index) distribution of Biology and Biochemistry scientists ranked by Research.com in 2026. The highlighted bar marks where Guillaume Lessene sits on this spectrum.

40–41 D-Index: 80 scientists 42–43 D-Index: 183 scientists 44–45 D-Index: 316 scientists 46–47 D-Index: 504 scientists 48–49 D-Index: 718 scientists 50–51 D-Index: 899 scientists 52–53 D-Index: 1,025 scientists 54–55 D-Index: 1,149 scientists 56–57 D-Index: 1,235 scientists 58–59 D-Index: 1,253 scientists 60–61 D-Index: 1,162 scientists 62–63 D-Index: 1,130 scientists 64–65 D-Index: 1,031 scientists 66–67 D-Index: 897 scientists 68–69 D-Index: 814 scientists 70–71 D-Index: 714 scientists 72–73 D-Index: 709 scientists 74–75 D-Index: 596 scientists 76–77 D-Index: 512 scientists 78–79 D-Index: 473 scientists 80–81 D-Index: 412 scientists 82–83 D-Index: 373 scientists 84–85 D-Index: 358 scientists 86–87 D-Index: 285 scientists 88–89 D-Index: 273 scientists 90–91 D-Index: 227 scientists 92–93 D-Index: 208 scientists 94–95 D-Index: 193 scientists 96–97 D-Index: 153 scientists 98–99 D-Index: 157 scientists 100–101 D-Index: 148 scientists 102–103 D-Index: 120 scientists 104–105 D-Index: 113 scientists 106–107 D-Index: 100 scientists 108–109 D-Index: 86 scientists 110–111 D-Index: 67 scientists 112–113 D-Index: 71 scientists 114–115 D-Index: 73 scientists 116–117 D-Index: 64 scientists 118–119 D-Index: 53 scientists 120–121 D-Index: 60 scientists 122–123 D-Index: 54 scientists 124–125 D-Index: 43 scientists 126–127 D-Index: 38 scientists 128–129 D-Index: 49 scientists 130–131 D-Index: 26 scientists 132–133 D-Index: 18 scientists 134–135 D-Index: 23 scientists 136–137 D-Index: 32 scientists 138–139 D-Index: 32 scientists 140–141 D-Index: 27 scientists 142–143 D-Index: 19 scientists 144–145 D-Index: 22 scientists 146–147 D-Index: 12 scientists 148–149 D-Index: 16 scientists 150–151 D-Index: 14 scientists 152–153 D-Index: 10 scientists 154–155 D-Index: 13 scientists 156–157 D-Index: 10 scientists 158–159 D-Index: 7 scientists 160–161 D-Index: 9 scientists 162–163 D-Index: 13 scientists 164–165 D-Index: 4 scientists 166 D-Index: 4 scientists 167+ D-Index: 98 scientists
40 D-Index 167+

This scientist: 50 D-Index — 11th percentile

11% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 167 D-Index or more.

Overview

Guillaume Lessene is affiliated with the Walter and Eliza Hall Institute of Medical Research in Australia. Their research primarily focuses on biochemistry, genetics, and molecular biology, with significant contributions to medicine. The subfields of study in which they have published include molecular biology, oncology, immunology, infectious diseases, and genetics.

Lessene's work often centers on cellular and molecular mechanisms, particularly those related to cell death and immune responses. The main topics of their research include:

  • Cell death mechanisms and regulation
  • Interferon and immune responses
  • SARS-CoV-2 and COVID-19 research
  • Protein degradation and inhibitors
  • Ubiquitin and proteasome pathways
  • Cancer-related molecular pathways
  • Chronic lymphocytic leukemia research

Among their recent publications are:

  • "Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2," 2020, The EMBO Journal
  • "MLKL trafficking and accumulation at the plasma membrane control the kinetics and threshold for necroptosis," 2020, Nature Communications
  • "The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs," 2021, Nature Reviews. Cancer
  • "Human RIPK3 maintains MLKL in an inactive conformation prior to cell death by necroptosis," 2021, Nature Communications
  • "Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia," 2022, Blood

Lessene has collaborated extensively with several co-authors, including Peter E. Czabotar, David C.S. Huang, Kym N. Lowes, Andreas Strasser, and Mark F. van Delft.

Their publications are frequently found in several notable venues such as:

  • bioRxiv (Cold Spring Harbor Laboratory)
  • Nature Communications
  • Cell Death and Differentiation
  • Cell Death and Disease
  • The EMBO Journal

Best Publications

  • Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy

    Peter E Czabotar;Guillaume Lessene;Andreas Strasser;Jerry M Adams

  • The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

    András Kotschy;Zoltán Szlavik;James Murray;James Davidson

  • Apoptotic Caspases Suppress mtDNA-Induced STING-Mediated Type I IFN Production

    Michael J. White;Michael J. White;Kate McArthur;Kate McArthur;Donald Metcalf;Donald Metcalf;Rachael M. Lane

  • BAK/BAX macropores facilitate mitochondrial herniation and mtDNA efflux during apoptosis

    Kate McArthur;Kate McArthur;Kate McArthur;Lachlan W. Whitehead;Lachlan W. Whitehead;John M. Heddleston;Lucy Li

  • BCL-2 family antagonists for cancer therapy

    Guillaume Lessene;Peter E. Czabotar;Peter M. Colman

  • Activation of the pseudokinase MLKL unleashes the four-helix bundle domain to induce membrane localization and necroptotic cell death

    Joanne M. Hildebrand;Maria C. Tanzer;Isabelle S. Lucet;Isabelle S. Lucet;Samuel N. Young

  • Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2.

    Theresa Klemm;Gregor Ebert;Dale J Calleja;Cody C Allison

  • Structure-guided design of a selective BCL-XL inhibitor

    Guillaume Lessene;Guillaume Lessene;Peter Edward Czabotar;Peter Edward Czabotar;Brad Sleebs;Brad Sleebs;Kerry Zobel

  • Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity

    Zhi-Fu Tao;Lisa Hasvold;Le Wang;Xilu Wang

  • BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines.

    Delphine Merino;Gemma L. Kelly;Guillaume Lessene;Andrew H. Wei

  • MLKL trafficking and accumulation at the plasma membrane control the kinetics and threshold for necroptosis

    Andre L Samson;Andre L Samson;Ying Zhang;Ying Zhang;Niall D Geoghegan;Niall D Geoghegan;Xavier J Gavin

  • The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs.

    Sarah T Diepstraten;Mary Ann Anderson;Peter E Czabotar;Peter E Czabotar;Guillaume Lessene;Guillaume Lessene

  • Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations

    Richard W. Birkinshaw;Richard W. Birkinshaw;Jia-nan Gong;Jia-nan Gong;Cindy S. Luo;Cindy S. Luo;Daisy Lio;Daisy Lio

  • The Mitochondrial Apoptotic Effectors BAX/BAK Activate Caspase-3 and -7 to Trigger NLRP3 Inflammasome and Caspase-8 Driven IL-1β Activation

    James E. Vince;James E. Vince;Dominic De Nardo;Dominic De Nardo;Wenqing Gao;Angelina J. Vince

  • Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer.

    Delphine Merino;Delphine Merino;James R. Whittle;James R. Whittle;James R. Whittle;François Vaillant;François Vaillant;Antonin Serrano;Antonin Serrano

  • Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1

    T. C. Teh;T. C. Teh;N. Y. Nguyen;D. M. Moujalled;D. Segal;D. Segal

  • Conformational switching of the pseudokinase domain promotes human MLKL tetramerization and cell death by necroptosis.

    Emma J. Petrie;Emma J. Petrie;Jarrod J. Sandow;Jarrod J. Sandow;Annette V. Jacobsen;Annette V. Jacobsen;Brian J. Smith

  • HSP90 activity is required for MLKL oligomerisation and membrane translocation and the induction of necroptotic cell death.

    A V Jacobsen;A V Jacobsen;K N Lowes;K N Lowes;M C Tanzer;M C Tanzer;I S Lucet;I S Lucet

  • Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia

    Donia M. Moujalled;Donia M. Moujalled;Giovanna Pomilio;Giovanna Pomilio;Corina Ghiurau;Adam Ivey

  • Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1.

    Jia Nan Gong;Jia Nan Gong;Tiffany Khong;David Segal;David Segal;Yuan Yao;Yuan Yao;Yuan Yao

Frequent Co-Authors

Peter E. Czabotar
Peter E. Czabotar Walter and Eliza Hall Institute of Medical Research
David C. S. Huang
David C. S. Huang Walter and Eliza Hall Institute of Medical Research
Jonathan B. Baell
Jonathan B. Baell Monash University
Peter M. Colman
Peter M. Colman Walter and Eliza Hall Institute of Medical Research
Brian J. Smith
Brian J. Smith QIMR Berghofer Medical Research Institute
Marco J. Herold
Marco J. Herold Walter and Eliza Hall Institute of Medical Research
Andreas Strasser
Andreas Strasser Walter and Eliza Hall Institute of Medical Research
James M. Murphy
James M. Murphy Walter and Eliza Hall Institute of Medical Research
Andrew W. Roberts
Andrew W. Roberts Walter and Eliza Hall Institute of Medical Research

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Best Scientists Citing Guillaume Lessene

Trending Scientists

Recently Published Articles